Beximco Pharmaceuticals Ltd (LON:BXP) (Dhaka:BXPH.DH), a pharmaceutical company in Bangladesh, will start selling a generic version of Merck & Co's (NYSE:MRK) antiviral pill for COVID-19 following local regulatory approval, Reuters news agency reported on Tuesday.
The company stated that it will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it had received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration.
This marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir.
Molnupiravir had received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.
Beximco added that exports would depend on regulatory approvals globally.
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules